

FOI 2418

28th May 2024

## FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

---

### Question 1:

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

### Response:

| Drug Name                | Number of Patients |
|--------------------------|--------------------|
| Abatacept [Orencia]      | 101                |
| Adalimumab [Humira]      | 35                 |
| Adalimumab Biosimilars   | 518                |
| Apremilast [Otezla]      | 1                  |
| Baricitinib [Olumiant]   | 48                 |
| Bimekizumab [Bimzelx]    | 3                  |
| Certolizumab [Cimzia]    | 71                 |
| Etanercept [Enbrel]      | 11                 |
| Etanercept Biosimilars   | 213                |
| Filgotinib [Jyseleca]    | 0                  |
| Golimumab [Simponi]      | 79                 |
| Guselkumab [Tremfya]     | 9                  |
| Infliximab [Remicade]    | 1                  |
| Infliximab Biosimilars   | 28                 |
| Ixekizumab [Taltz]       | 57                 |
| Risankizumab [Skyrizi]   | 1                  |
| Rituximab [MabThera]     | 0                  |
| Rituximab Biosimilars    | 113                |
| Sarilumab [Kevzara]      | 16                 |
| Secukinumab [Cosentyx]   | 143                |
| Tocilizumab [Ro Actemra] | 42                 |
| Tocilizumab Biosimilars  | 3                  |
| Tofacitinib [Xeljanz]    | 11                 |
| Upadacitinib [Rinvoq]    | 18                 |
| Ustekinumab [Stelara]    | 0                  |

**Question 2:**

**Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:**

**Response:**

| <b>Drug Name</b>              | <b>Number of Patients</b> |
|-------------------------------|---------------------------|
| <b>Abatacept [Orencia]</b>    | 0                         |
| <b>Adalimumab [Humira]</b>    | 14                        |
| <b>Adalimumab Biosimilars</b> | 173                       |
| <b>Apremilast [Otezla]</b>    | 0                         |
| <b>Bimekizumab [Bimzelx]</b>  | 1                         |
| <b>Certolizumab [Cimzia]</b>  | 26                        |
| <b>Etanercept [Enbrel]</b>    | 4                         |
| <b>Etanercept Biosimilars</b> | 65                        |
| <b>Golimumab [Simponi]</b>    | 25                        |
| <b>Guselkumab [Tremfya]</b>   | 8                         |
| <b>Infliximab [Remicade]</b>  | 0                         |
| <b>Infliximab Biosimilars</b> | 8                         |
| <b>Ixekizumab [Taltz]</b>     | 39                        |
| <b>Risankizumab [Skyrizi]</b> | 1                         |
| <b>Secukinumab [Cosentyx]</b> | 84                        |
| <b>Tofacitinib [Xeljanz]</b>  | 5                         |
| <b>Upadacitinib [Rinvoq]</b>  | 3                         |
| <b>Ustekinumab [Stelara]</b>  | 0                         |

**Email:** [FOI.team@southerntrust.hscni.net](mailto:FOI.team@southerntrust.hscni.net)